RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported that its experimental hypertension drug lorundrostat maintained significant blood pressure reductions through 48 weeks of treatment, providing additional clinical…
RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported that its experimental hypertension drug lorundrostat maintained significant blood pressure reductions through 48 weeks of treatment, providing additional clinical evidence as …
This is a source-linked briefing. Read the original report from Mychesco .